Lineage Cell Therapeutics, Inc.
LCTX
$1.68
$0.074.35%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.68M | 2.77M | 1.50M | 2.87M | 3.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.68M | 2.77M | 1.50M | 2.87M | 3.78M |
| Cost of Revenue | 184.00K | 3.15M | 2.98M | 3.58M | 210.00K |
| Gross Profit | 3.50M | -380.00K | -1.48M | -709.00K | 3.57M |
| SG&A Expenses | 4.19M | 4.56M | 4.86M | 4.40M | 4.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.47M | 7.71M | 8.01M | 7.98M | 7.62M |
| Operating Income | -3.79M | -4.94M | -6.51M | -5.11M | -3.84M |
| Income Before Tax | -29.75M | -30.36M | -4.14M | -3.25M | -3.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.75M | -30.36M | -4.14M | -3.25M | -3.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -29.00K | -100.00K | 4.00K | -23.00K | -33.00K |
| Net Income | -29.78M | -30.46M | -4.14M | -3.27M | -3.03M |
| EBIT | -3.79M | -4.94M | -6.51M | -5.11M | -3.84M |
| EBITDA | -3.61M | -4.77M | -6.34M | -4.96M | -3.70M |
| EPS Basic | -0.13 | -0.13 | -0.02 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.08 | -0.04 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.13 | -0.13 | -0.02 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.08 | -0.04 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 228.85M | 228.36M | 226.05M | 240.19M | 188.84M |
| Average Diluted Shares Outstanding | 228.85M | 228.36M | 226.05M | 240.19M | 188.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |